BriaCell Therapeutics Corp. (BCTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BriaCell Therapeutics Corp. (BCTX) trades at $3.50 with AI Score 43/100 (Grade C). BriaCell Therapeutics Corp. is a biotechnology company focused on developing immunotherapies for cancer treatment. Market cap: $6.59M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for BCTX: BCTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BCTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BCTX: the 1 perspectives are evenly split.
How is this calculated? →BriaCell Therapeutics Corp. (BCTX) Healthcare & Pipeline Overview
BriaCell Therapeutics Corp. is an immuno-oncology company developing novel immunotherapies, including Bria-IMT, currently in Phase I/IIa clinical trials for breast cancer treatment. The company collaborates with the National Cancer Institute to advance personalized cancer treatments, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for BCTX?
BriaCell Therapeutics Corp. presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The primary value driver is the clinical progress of Bria-IMT, with successful Phase IIa trial results potentially leading to significant stock appreciation. The collaboration with the NCI for Bria-OTS adds credibility and potential for future personalized cancer therapies. However, the company's small market capitalization of $6.59M and limited resources pose substantial risks. Upcoming data readouts from the Bria-IMT trial and advancements in the Bria-OTS program are key catalysts. Failure to achieve positive clinical outcomes or secure additional funding could negatively impact the company's prospects. Investors should closely monitor clinical trial results, partnership developments, and financial stability.
Based on FMP financials and quantitative analysis
BCTX Key Highlights
- Bria-IMT is in Phase I/IIa clinical trial in combination with immune checkpoint inhibitors for breast cancer treatment.
- Cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer.
- Developing BriaDx, a diagnostic test to identify patients most likely to respond to BriaCell's immunotherapies.
- Market capitalization of $6.59M indicates a small-cap biotechnology company.
- The company has 16 employees, reflecting its focus on efficient research and development.
Who Are BCTX's Competitors?
BCTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $81.41 | +2.06% | $32.30B | — |
| PFE Pfizer Inc. | $23.73 | -2.43% | $135.25B | 64 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BCTX's Key Strengths?
- Innovative immunotherapy technology.
- Collaboration with the National Cancer Institute.
- Focus on personalized medicine.
- Lead candidate in clinical trials.
What Are BCTX's Weaknesses?
- Limited financial resources.
- Small number of employees.
- Early-stage clinical development.
- High risk of clinical trial failure.
What Could Drive BCTX Stock Higher?
- Data readouts from the Phase I/IIa clinical trial of Bria-IMT in combination with immune checkpoint inhibitors for breast cancer.
- Potential announcement of new strategic partnerships or collaborations with pharmaceutical companies.
- Continued development and advancement of Bria-OTS in collaboration with the National Cancer Institute.
- Progress in the development and validation of BriaDx as a diagnostic tool.
What Are the Key Risks for BCTX?
- Financial-distress signal — its Altman Z-Score of -9.21 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in clinical trials, leading to delays or termination of development programs.
- Inability to secure additional funding to support ongoing research and development activities.
- Competition from larger pharmaceutical companies with more resources and established market presence.
- Regulatory hurdles and potential delays in obtaining regulatory approvals for BriaCell's therapies.
- Intellectual property challenges or infringement claims.
What Are the Growth Opportunities for BCTX?
- Advancement of Bria-IMT through Clinical Trials: BriaCell's lead candidate, Bria-IMT, is currently in Phase I/IIa clinical trials for advanced breast cancer. Positive results from these trials could lead to further development and potential FDA approval, tapping into the multi-billion dollar breast cancer treatment market. The timeline for potential commercialization depends on trial outcomes, but successful data could significantly increase the company's value within the next 2-3 years.
- Development of Bria-OTS Personalized Immunotherapy: BriaCell's collaboration with the National Cancer Institute (NCI) to develop Bria-OTS, a personalized immunotherapy, represents a significant growth opportunity. Personalized medicine is a rapidly expanding field, and successful development of Bria-OTS could position BriaCell as a leader in this space. The market for personalized cancer therapies is projected to reach billions of dollars within the next 5 years, offering substantial revenue potential.
- Expansion of BriaDx Diagnostic Test: The development of BriaDx, a diagnostic test to identify patients most likely to respond to BriaCell's immunotherapies, can improve treatment outcomes and reduce healthcare costs. A successful diagnostic test could be commercialized independently or in conjunction with Bria-IMT and Bria-OTS, creating a synergistic effect. The market for cancer diagnostics is substantial and growing, providing a valuable revenue stream for BriaCell.
- Strategic Partnerships and Collaborations: BriaCell can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its immunotherapies. These partnerships can provide access to funding, expertise, and distribution networks, significantly enhancing BriaCell's growth prospects. The immuno-oncology market is characterized by frequent collaborations, and BriaCell's innovative approach makes it an attractive partner.
- Expansion into New Cancer Indications: While BriaCell's initial focus is on breast cancer, its immunotherapies have the potential to be effective against other types of cancer. Expanding into new cancer indications would significantly broaden the company's market opportunity and revenue potential. This expansion would require additional research and development, but the potential rewards are substantial, given the global burden of cancer.
What Opportunities Does BCTX Have?
- Positive clinical trial results.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new cancer indications.
- Advancements in personalized medicine.
What Threats Does BCTX Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and approval delays.
- Failure to secure additional funding.
- Negative clinical trial results.
What Are BCTX's Competitive Advantages?
- Proprietary immunotherapy technology: BriaCell's unique approach to developing personalized cancer immunotherapies provides a competitive advantage.
- Collaboration with the National Cancer Institute: The CRADA with the NCI lends credibility and access to resources.
- Focus on personalized medicine: The development of Bria-OTS and BriaDx positions BriaCell in the growing personalized medicine market.
- Intellectual property protection: Patents and other intellectual property rights protect BriaCell's technologies and products.
What Does BCTX Do?
Founded with the mission to revolutionize cancer treatment through innovative immunotherapies, BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted treatments for cancer patients. The company's lead candidate, Bria-IMT, is currently in Phase I/IIa clinical trials, evaluating its efficacy in combination with immune checkpoint inhibitors for the treatment of advanced breast cancer. This trial is a crucial step in determining the potential of Bria-IMT to improve patient outcomes in a disease with significant unmet needs. Beyond Bria-IMT, BriaCell is also developing Bria-OTS, a personalized immunotherapy designed to target specific cancer mutations within individual patients. This program is being advanced through a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI), highlighting the scientific rigor and potential of BriaCell's approach. The company is also working on BriaDx, a diagnostic test aimed at identifying patients most likely to respond to BriaCell's immunotherapies. Headquartered in West Vancouver, Canada, BriaCell operates with a lean team of 16 employees, reflecting its focus on efficient research and development. The company's strategic collaborations and innovative pipeline position it as a player in the competitive immuno-oncology market, striving to deliver personalized and effective cancer treatments.
What Products and Services Does BCTX Offer?
- Develop immunotherapies for cancer treatment.
- Conduct clinical trials for their lead candidate, Bria-IMT, in combination with immune checkpoint inhibitors for breast cancer.
- Collaborate with the National Cancer Institute to develop Bria-OTS, a personalized immunotherapy for advanced breast cancer.
- Develop BriaDx, a diagnostic test to identify patients most likely to respond to their immunotherapies.
- Focus on personalized medicine approaches to cancer treatment.
- Engage in research and development to expand their pipeline of cancer therapies.
How Does BCTX Make Money?
- Develop and commercialize immunotherapies for cancer treatment.
- Generate revenue through partnerships and collaborations with pharmaceutical companies.
- Potentially generate revenue through the sale of diagnostic tests like BriaDx.
- Secure funding through grants, venture capital, and public offerings.
What Industry Does BCTX Operate In?
BriaCell operates within the competitive and rapidly evolving immuno-oncology sector. This sector is characterized by high growth and significant investment, driven by the increasing prevalence of cancer and the demand for more effective and personalized treatments. Key trends include the development of immune checkpoint inhibitors, CAR-T cell therapies, and personalized cancer vaccines. BriaCell's focus on developing immunotherapies, particularly its personalized approach with Bria-OTS, aligns with these trends. The company competes with larger pharmaceutical companies and specialized biotech firms, requiring strategic partnerships and efficient use of capital to succeed.
Who Are BCTX's Key Customers?
- Cancer patients, particularly those with advanced breast cancer.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies seeking to collaborate on cancer therapies.
- Research institutions and government agencies (e.g., National Cancer Institute).
FY2026 estForward Outlook
Wall Street analysts project BriaCell Therapeutics Corp. revenue of about $2.1M for fiscal 2026, with EPS near $-11.45.
BCTX Valuation & Market Position
With a $6.59M market cap, BriaCell Therapeutics Corp. sits in the micro-cap segment of the market. Relative to its peer group, BCTX's quantitative score of 43/100 is below the peer average of 78/100.
Key Financial Metrics
Return on assets is -88.2%, showing how much profit it generates from its asset base. A current ratio of 10.19 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
BriaCell Therapeutics Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.21 places it in the distress zone, a signal of elevated financial risk.
Company Profile
BriaCell Therapeutics Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in West Vancouver, CA. The company is led by CEO William V. Williams. BCTX has traded publicly since 2012.
BCTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- BCTX insiders seem to be showing confidence lately, which often signals they believe the company is undervalued.
- There's a growing buzz in the community about BCTX's potential, suggesting increased market awareness.
- Recent developments in the sector might shine a positive light on BCTX's approach to cancer treatment.
- The community is starting to see BCTX as a disruptor, potentially leading to a re-evaluation of its market position.
Bear Case
- Despite the hype, some investors are worried about BCTX's long-term funding.
- The community is also discussing concerns about competition in the cancer treatment space.
- Recent market turbulence has made investors more risk-averse, potentially impacting BCTX's stock.
- There's some skepticism in the community about the timeline for BCTX to bring its treatments to market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BCTX Latest News
No recent news available for BCTX.
BCTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCTX.
Price Targets
Wall Street price target analysis for BCTX.
BCTX MoonshotScore
What does this score mean?
The MoonshotScore rates BCTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William V. Williams
CEO
William V. Williams serves as the CEO of BriaCell Therapeutics Corp., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies focused on drug development and commercialization. Williams has a strong track record in strategic planning, business development, and fundraising. He is responsible for guiding BriaCell's overall strategy and operations, including the advancement of its clinical programs and the expansion of its partnerships.
Track Record: Under William V. Williams' leadership, BriaCell has advanced its lead candidate, Bria-IMT, into Phase I/IIa clinical trials. He has also overseen the company's collaboration with the National Cancer Institute for the development of Bria-OTS. His focus on strategic partnerships and efficient resource allocation has been crucial in navigating the challenges of early-stage drug development. He manages 16 employees.
BriaCell Therapeutics Corp. Healthcare Stock: Key Questions Answered
What does BriaCell Therapeutics Corp. do?
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company focused on developing novel immunotherapies to combat cancer. Their primary focus is on Bria-IMT, currently in Phase I/IIa clinical trials for advanced breast cancer, combining it with immune checkpoint inhibitors. Additionally, they are collaborating with the National Cancer Institute (NCI) to develop Bria-OTS, a personalized immunotherapy, and BriaDx, a diagnostic test to identify patients most likely to respond to their treatments. The company aims to revolutionize cancer treatment through personalized and effective immunotherapeutic approaches.
What do analysts say about BCTX stock?
As of May 9, 2026, analyst coverage of BCTX stock is limited, reflecting its small-cap status and early-stage clinical development. Key valuation metrics are heavily dependent on the success of Bria-IMT's clinical trials and the potential for future partnerships. Growth considerations revolve around the advancement of Bria-OTS and the commercialization of BriaDx. Investors should conduct thorough due diligence and consider the inherent risks associated with biotechnology companies in early stages of development.
What are the main risks for BCTX?
The main risks for BriaCell Therapeutics Corp. include the inherent uncertainties of clinical trial outcomes, particularly for Bria-IMT. Failure to demonstrate efficacy or safety in ongoing trials could significantly impact the company's value. Additionally, BriaCell faces financial risks due to its limited resources and reliance on securing additional funding. Competition from larger pharmaceutical companies and regulatory hurdles also pose significant challenges. Investors should be aware of these risks and the potential for volatility in the stock price.
What is BriaCell Therapeutics Corp.'s drug pipeline status?
BriaCell Therapeutics Corp.'s drug pipeline is primarily focused on its lead candidate, Bria-IMT, which is currently in Phase I/IIa clinical trials for advanced breast cancer. This trial assesses the efficacy of Bria-IMT in combination with immune checkpoint inhibitors. The company is also developing Bria-OTS, a personalized immunotherapy for advanced breast cancer, in collaboration with the National Cancer Institute. Key upcoming catalysts include data readouts from the Bria-IMT trial and potential advancements in the Bria-OTS program, which will determine the future direction of the company's clinical development efforts.
How does BriaCell Therapeutics Corp. navigate regulatory approval processes?
As a biotechnology company developing novel immunotherapies, BriaCell Therapeutics Corp. must navigate rigorous regulatory approval processes, primarily with the FDA in the United States. The company's strategy involves conducting well-designed clinical trials to demonstrate the safety and efficacy of its lead candidate, Bria-IMT. BriaCell's collaboration with the National Cancer Institute (NCI) for Bria-OTS also provides access to regulatory expertise and resources. The company's compliance strategy focuses on adhering to FDA guidelines and maintaining open communication with regulatory agencies throughout the development process. The success of BriaCell's regulatory efforts will be crucial for the eventual commercialization of its therapies.
What are the key factors to evaluate for BCTX?
BriaCell Therapeutics Corp. (BCTX) holds an AI score of 43/100 (low). Not financial advice.
How frequently does BCTX data refresh on this page?
BCTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BCTX's recent stock price performance?
BriaCell Therapeutics Corp. (BCTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative immunotherapy technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- Future clinical trial results may significantly impact the company's prospects.
- Investment in biotechnology companies is inherently risky.